Endpoints
SECONDARY
The primary objective of this clinical trial was to validate the feasibility and safety of autologous GD2-specific 4SCAR-T cell infusion in patients with GBM. The secondary objective was to determine 4SCAR-T cell expansion, persistence, and anti-GBM effects.